Описание деятельности
Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Правление & Наблюдательный совет
| Исполнительный директор |
| Yvonne Greenstreet |
| Правление |
| Jeff Poulton, Akshay Vaishnaw, Pushkal Garg, Kelley Boucher, Tim Maines, Tolga Tanguler, Indrani Franchini, Piyush Sharma, Evan Lippman, Kevin Fitzgerald |
| Наблюдательный совет |
| Amy W. Schulman, Dennis A. Ausiello, Carolyn Bertozzi, Michael W. Bonney, Olivier Brandicourt, Marsha H. Fanucci, Yvonne Greenstreet, Margaret A. Hamburg, Peter N. Kellogg, David E.I. Pyott, Colleen F. Reitan, Phillip A. Sharp, Elliott Sigal |
Данные компании
| Имя: |
Alnylam Pharmaceuticals, Inc |
| Адрес: |
675 West Kendall St,Cambridge, MA 02142 |
| Телефон: |
+1 617-551-8200 |
| Факс: |
+1 617-551-8101 |
| E-mail: |
INFO@ALNYLAM.COM
|
| Интернет: |
https://www.alnylam.com/ |
| Индустрия: |
Biotechnology |
| Сектор: |
Biotechnology |
| Подсектор: |
- |
| Конец финансового года: |
31.12 |
| Акции в свободном обращении: |
- |
| Дата IPO: |
01.05.2004 |
